Moleculin Biotech, Inc. Deferred Foreign Income Tax Expense (Benefit)
Moleculin Biotech, Inc. (MBRX) reported Deferred Foreign Income Tax Expense (Benefit) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2025-03-21
- Moleculin Biotech, Inc. deferred foreign income tax expense (benefit) for fiscal 2024 was $0.00.
- Moleculin Biotech, Inc. deferred foreign income tax expense (benefit) for fiscal 2023 was $0.00.
- Moleculin Biotech, Inc. deferred foreign income tax expense (benefit) for fiscal 2022 was $0.00.
- Moleculin Biotech, Inc. deferred foreign income tax expense (benefit) for fiscal 2021 was $0.00.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-21 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-21 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-22 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-22 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-24 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-24 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |